




Article

# Melatonin Modulation of Radiation and Chemotherapeutics-induced Changes on Differentiation of Breast Fibroblasts

Alicia González-González <sup>1</sup>, Enrique García Nieto <sup>1</sup>, Alicia González <sup>1,\*</sup>, Cristina Sánchez-Fernández <sup>3</sup>, Carolina Alonso-González <sup>1,\*</sup>, Javier Menéndez-Menéndez <sup>1</sup>, José Gómez-Arozamena <sup>2</sup>, Samuel Cos <sup>1</sup> and Carlos Martínez-Campa <sup>1</sup> 

<sup>1</sup> Department of Physiology and Pharmacology, School of Medicine, University of Cantabria and Instituto de Investigación Sanitaria Valdecilla (IDIVAL), 39011 Santander, Spain

<sup>2</sup> Department of Medical Physics, School of Medicine, University of Cantabria, 39011 Santander, Spain

<sup>3</sup> Department of Anatomy and Cellular Biology, School of Medicine, University of Cantabria, 39011 Santander, Spain

\* Correspondence: gonzalavl@unican.es (A.G.); alonsogc@unican.es (C.A.-G.)

Received: 11 July 2019; Accepted: 10 August 2019; Published: 13 August 2019



**Abstract:** Melatonin exerts oncostatic actions and sensitizes tumor cells to chemotherapeutics or radiation. In our study, we investigated the effects of docetaxel, vinorelbine, and radiation on human breast fibroblasts and its modulation by melatonin. Docetaxel or vinorelbine inhibits proliferation and stimulates the differentiation of breast preadipocytes, by increasing C/EBP $\alpha$  and PPAR $\gamma$  expression and by downregulating tumor necrosis factor  $\alpha$  (TNF $\alpha$ ), interleukin 6 (IL-6), and IL-11 expression. Radiation inhibits both proliferation and differentiation through the downregulation of C/EBP $\alpha$  and PPAR $\gamma$  and by stimulating TNF $\alpha$  expression. In addition, docetaxel and radiation decrease aromatase activity and expression by decreasing aromatase promoter II and cyclooxygenases 1 and 2 (COX-1 and COX-2) expression. Melatonin potentiates the stimulatory effect of docetaxel and vinorelbine on differentiation and their inhibitory effects on aromatase activity and expression, by increasing the stimulatory effect on C/EBP $\alpha$  and PPAR $\gamma$  expression and the downregulation of antiadipogenic cytokines and COX expression. Melatonin also counteracts the inhibitory effect of radiation on differentiation of preadipocytes, by increasing C/EBP $\alpha$  and PPAR $\gamma$  expression and by decreasing TNF $\alpha$  expression. Melatonin also potentiates the inhibitory effect exerted by radiation on aromatase activity and expression by increasing the downregulation of promoter II, and COX-1 and COX-2 expression. Our findings suggest that melatonin modulates regulatory effects induced by chemotherapeutic drugs or radiation on preadipocytes, which makes it a promising adjuvant for chemotherapy and radiotherapy sensitization.

**Keywords:** melatonin; breast cancer; aromatase; adipocyte; differentiation

## 1. Introduction

The growth of malignant cells is conditioned by tumor microenvironment. Normal cells that are close to the tumor cells provide them a structural support, but they are also an active component in tumor evolution. Among the different types of cells that surround malignant cells, the fibroblasts of the adipose tissue and preadipocytes are in large numbers, which are undifferentiated fibroblasts that are able to become adipocytes after adequate stimulation. The mammary adipose tissue in breast cancer not only affects the progression of the tumor but also can affect the initial stages of carcinogenesis and the response to treatment [1,2]. Fibroblasts are a main cellular element in the tumor microenvironment and epithelial–stromal interactions inhibit adipogenic differentiation and

increase estrogen synthesis generating a layer of undifferentiated fibroblast with high capacity to produce estrogens around the malignant epithelial cells [1,2]. Thus, adipose cells close to tumor cells have the most aromatase expression, the enzyme that transforms androgens into estrogens, in breast tumors. Besides, the amount of adipose tissue around breast malignant cells is very large. In addition, fibroblasts close to malignant cells show the most intense aromatase immunostaining and aromatase activity and expression are 10–15 times higher than those found in malignant epithelial cells [3]. It is known that malignant epithelial cells secrete antiadipogenic cytokines, such as TNF- $\alpha$ , IL-11, and IL-6 that inhibit the differentiation of fibroblasts near the tumor into mature adipocytes and stimulate aromatase expression in these undifferentiated adipose fibroblasts [4]. This blockage caused by the tumor cells in adipocyte differentiation is mediated by the inhibition of expression of the two main adipogenic transcription factors CCAAT/enhancer-binding protein (C/EBP) $\alpha$  and peroxisome proliferator-activated receptor (PPAR $\gamma$ ) [4]. Regulation of aromatase expression involves alternative promoter sites that support tissue-specific control. In breast cancer cells and peritumoral fibroblasts, the expression of aromatase depend on activation of promoters II and I.3 which are stimulated by prostaglandin E<sub>2</sub> [3]. However, in normal breast, the low level of aromatase expression is due to the activation of promoter I.4 [5].

At this moment, radiation and chemotherapeutic agents play an important role in breast cancer treatment. Both therapies have positive effects on the treatment of different tumors but they have also negative side effects that repress their use since they affect the quality of life of many patients. In vivo and in vitro studies have described that irradiation exposure induces changes in adipose tissue, such as a decrease in size and number of mature adipocyte and a decrease in cell proliferation and adipogenic differentiation [6]. However, the effects of chemotherapeutic agents, such as docetaxel or vinorelbine, on adipose tissue are not known.


Melatonin, produced mainly by the pineal gland, exerts antitumor actions in different kinds of tumors but especially on hormone-dependent mammary tumors [7–9]. In this sense, melatonin not only decreases the situations that lead to the generation of cancer, but also exerts oncostatic actions through different mechanisms of action [9,10]. In addition, in the last years, it has been demonstrated that melatonin can sensitize tumor cells to chemotherapeutics or radiation by increasing their therapeutic effects [11–14]. In this study, we investigated the effects of ionizing radiation or chemotherapeutics, like docetaxel or vinorelbine, no longer on tumor cells but on normal cells, particularly human mammary fibroblasts, a kind of cell crucial in tumor microenvironment, and its modulation by melatonin.

## 2. Results


### 2.1. Effects of Melatonin on Docetaxel- and Vinorelbine-Induced Changes on Adipose Differentiation of Human Breast Preadipocytes

Firstly, we investigated the effects of docetaxel and vinorelbine added to the cell cultures during the course of adipose differentiation. As shown in Figure 1, docetaxel 1  $\mu$ M and vinorelbine 1  $\mu$ M reduced cell proliferation and increased the triglyceride content of adipocytes, an indicator of adipogenic differentiation. Melatonin 1 mM and 1 nM treatment also decreased cell proliferation and significantly stimulated ( $p < 0.001$ ) adipogenesis. In addition, only melatonin 1 mM potentiated the inhibitory effect on cell proliferation and the stimulatory effect of docetaxel and vinorelbine on differentiation of breast preadipocytes.

Secondly, we studied the effects of docetaxel, vinorelbine, and melatonin on differentiated human breast preadipocytes. Treatment of breast adipocytes previously differentiated with docetaxel 1  $\mu$ M or vinorelbine 1  $\mu$ M for 3 days also induced a decrease in cell proliferation but did not modified significantly the intracytoplasmic triglyceride accumulation of the cells (Figure 2). Melatonin only at 1 mM concentration also decreased cell proliferation and increased intracytoplasmic triglyceride accumulation in combination with docetaxel or vinorelbine.




**Figure 1.** Effects of melatonin 1 mM or 1 nM on docetaxel- and vinorelbine-induced changes on (A) cell proliferation and (B) intracytoplasmic triglyceride content, during the course of differentiation of human breast adipocytes. Cell proliferation was quantified by the MTT method and triglyceride accumulation using the Oil Red O staining method. Data are expressed as the percentage of the control group (mean ± standard error of the mean (SEM)). a,  $p < 0.001$  vs. C; b,  $p < 0.05$  vs. C; c,  $p < 0.001$  vs. M (1 mM); d,  $p < 0.001$  vs. D (1 μM); e,  $p < 0.001$  vs. V (1 μM). C: control, M: melatonin, D: docetaxel, V: vinorelbine.



**Figure 2.** Effects of melatonin on docetaxel- and vinorelbine-induced changes on (A) cell proliferation and (B) intracytoplasmic triglyceride content on differentiating human breast adipocytes. Breast preadipocytes completely differentiated into adipocytes were treated with docetaxel (1 μM), vinorelbine (1 μM), and/or melatonin (1 mM or 1 nM) for 3 days. (A) Cell proliferation was measured by the MTT method. (B) Intracytoplasmic triglyceride accumulation was quantified by the Oil Red O staining method. Data are expressed as the percentage of the control group (mean ± SEM). a,  $p < 0.001$  vs. C; b,  $p < 0.001$  vs. M (1 mM); c,  $p < 0.001$  vs. D (1 μM); d,  $p < 0.001$  vs. V (1 μM). C: control, M: melatonin, D: docetaxel, V: vinorelbine.

Then, since malignant cells secrete cytokines that prevent the differentiation of preadipocytes to adipocytes, we studied the effects of docetaxel, vinorelbine, and melatonin on adipogenic differentiation, in co-cultures of human breast preadipocytes and human breast cancer cells. According to previous findings, the presence of malignant epithelial cells decreased triglyceride content. Docetaxel and vinorelbine increased adipogenic differentiation. Melatonin only at 1 mM concentration stimulated adipogenesis differentiation and potentiated the stimulatory effect induced by docetaxel and vinorelbine (Figure 3).




**Figure 3.** (A) Effects of melatonin on docetaxel- and vinorelbine-induced changes on intracytoplasmic triglyceride content in breast fibroblasts during the course of differentiation, in the presence of human breast cancer cells (MCF-7). Data are expressed as the percentage of the differentiated adipocytes (C) (mean  $\pm$  SEM). a,  $p < 0.001$  vs. C; b,  $p < 0.05$  vs. C; c,  $p < 0.001$  vs. differentiated adipocytes co-cultured with MCF-7 cells; d,  $p < 0.001$  vs. differentiated adipocytes co-cultured with MCF-7 cells and docetaxel (D, 1  $\mu$ M); e,  $p < 0.05$  vs. differentiated adipocytes co-cultured with MCF-7 cells and D (1  $\mu$ M) and melatonin (M, 1 mM); f,  $p < 0.001$  vs. differentiated adipocytes co-cultured with MCF-7 cells and vinorelbine (V, 1  $\mu$ M). (B) Representative images of the Oil Red O staining.


## 2.2. Effects of Melatonin on Radiation-Induced Changes on Adipose Differentiation of Human Breast Preadipocytes

Ionizing radiation reduced significantly ( $p < 0.001$ ) cell proliferation and intracytoplasmic triglyceride content. Melatonin (1 mM) decreased cell proliferation and counteracted the effect of radiation and increased adipogenesis differentiation (Figure 4).

In co-cultures of human breast preadipocytes and human breast cancer cells, ionizing radiation also decreased triglyceride content, and melatonin at both concentrations counteracted the effect of radiation and increased significantly adipogenesis differentiation (Figure 5).




**Figure 4.** Effects of melatonin (1 mM or 1 nM) on radiation-induced changes on (A) cell proliferation and (B) intracytoplasmic triglyceride content, during the course of differentiation of human breast adipocytes. Cell proliferation was quantified by the MTT method and triglyceride accumulation using the Oil Red O staining method. Data are expressed as the percentage of the control group (mean ± SEM). a,  $p < 0.001$  vs. C; b,  $p < 0.001$  vs. R; c,  $p < 0.001$  vs. R & M 1 mM. C: control, M: melatonin, R: radiation.



**Figure 5.** (A) Effects of melatonin on radiation-induced changes on intracytoplasmic triglyceride content in breast fibroblasts during the course of differentiation, in the presence of human breast cancer cells (MCF-7). Data are expressed as the percentage of the differentiated adipocytes (C) (mean ± SEM). a,  $p < 0.001$  vs. C; b,  $p < 0.05$  vs. C; c,  $p < 0.001$  vs. differentiated adipocytes co-cultured with MCF-7 cells; d,  $p < 0.05$  vs. differentiated adipocytes co-cultured with MCF-7 cells and radiated; e,  $p < 0.001$  vs. differentiated adipocytes co-cultured with MCF-7 cells, radiation, and melatonin (1 mM). (B) Representative images of the Oil Red O staining. C: control, M: melatonin, R: radiation.

### 2.3. Effects of Melatonin on Docetaxel-, Vinorelbine-, and Radiation-Induced Changes on C/EBP $\alpha$ and PPAR $\gamma$ Expression in Human Breast Preadipocytes

Since the maintenance of the adipose phenotype depends on the expression of some specific transcription factors like C/EBP $\alpha$  and PPAR $\gamma$ , we analyzed by RT-PCR the effects of docetaxel, vinorelbine, and radiation with or without melatonin during the course of adipose differentiation on the expression of these transcription factors. Docetaxel and vinorelbine significantly increased C/EBP $\alpha$  and PPAR $\gamma$  mRNA expression. Melatonin pretreatment potentiated the stimulatory effect of chemotherapeutics on both C/EBP $\alpha$  and PPAR $\gamma$  mRNA expression. Radiation decreased C/EBP $\alpha$  and PPAR $\gamma$  mRNA expression. Melatonin counteracted the inhibitory effect exerted by radiation and significantly increased C/EBP $\alpha$  and PPAR $\gamma$  mRNA expression (Figure 6).




**Figure 6.** Effects of melatonin on docetaxel-, vinorelbine-, and radiation-induced changes on (A) PPAR $\gamma$  and (B) C/EBP $\alpha$  mRNA expression. Data are expressed as the percentage of control group (mean  $\pm$  SEM). a,  $p < 0.01$  vs. C; b,  $p < 0.05$  vs. D (1  $\mu$ M); c,  $p < 0.01$  vs. V (1  $\mu$ M); d,  $p < 0.01$  vs. R. C: control, M: melatonin, D: docetaxel, V: vinorelbine, R: radiation.


### 2.4. Effects of Melatonin on Docetaxel-, Vinorelbine-, and Radiation-Induced Changes on Aromatase Activity and Expression of Human Breast Preadipocytes

Since aromatase activity and expression is also considered a marked undifferentiated preadipocyte phenotype, we measured aromatase activity and expression in human breast preadipocytes and its modulation by docetaxel, vinorelbine, or radiation in the presence or not of melatonin. As shown in Figure 7, docetaxel and ionizing radiation decreased aromatase activity and expression. Melatonin inhibited aromatase activity and expression and potentiated the inhibitory effect induced by docetaxel and radiation.

With the aim of determining whether the inhibitory effect of docetaxel and radiation on aromatase activity and expression is due to the downregulation of the main aromatase promoters I.3 and II in adipocytes, we measured, by RT-PCR, the mRNA expression of both aromatase promoters. Both docetaxel and radiation decreased aromatase promoter II mRNA expression. Melatonin inhibited both aromatase promoter I.3 and II mRNA expression and potentiated the inhibitory effect induced by docetaxel and radiation on aromatase promoter II mRNA expression (Figure 8).



**Figure 7.** Effects of melatonin on docetaxel-, vinorelbine-, and radiation-induced changes on (A) aromatase activity and (B) aromatase mRNA expression. Data are expressed as the percentage of control group (mean ± SEM). a,  $p < 0.05$  vs. C; b,  $p < 0.001$  vs. C; c,  $p < 0.001$  vs. D (1 μM); d,  $p < 0.01$  vs. V (1 μM); e,  $p < 0.001$  vs. R. C: control, M: melatonin, D: docetaxel, V: vinorelbine, R: radiation.




**Figure 8.** Effects of melatonin on docetaxel-, vinorelbine-, and radiation-induced changes on (A) aromatase promoter I.3 and (B) aromatase promoter II mRNA expression. Data are expressed as the percentage of control group (mean ± SEM). a,  $p < 0.05$  vs. C; b,  $p < 0.001$  vs. C; c,  $p < 0.001$  vs. D (1 μM); d,  $p < 0.001$  vs. V (1 μM); e,  $p < 0.001$  vs. R. C: control, M: melatonin, D: docetaxel, V: vinorelbine, R: radiation.



### 2.5. Effects of Melatonin on Docetaxel-, Vinorelbine-, and Radiation-Induced Changes on Tumor Necrosis Factor $\alpha$ (TNF $\alpha$ ), Interleukin 6 (IL-6), and IL-11 mRNA Expression in Human Breast Preadipocytes

Since cytokines, such as TNF $\alpha$ , IL-6, and IL-11, secreted by malignant cells inhibit the differentiation of preadipocytes to adipocytes and stimulate their aromatase expression, we studied the effects of melatonin on docetaxel-, vinorelbine-, and radiation-induced changes on the expression of these cytokines. Docetaxel inhibited the expression of all three antiadipogenic cytokines. Vinorelbine reduced TNF $\alpha$  and IL-11 mRNA expression. Radiation increased TNF $\alpha$  mRNA expression. Melatonin induced a reduction of TNF $\alpha$ , IL-6, and IL-11 mRNA levels and significantly increased the inhibitory effect of docetaxel on these cytokines and the inhibitory effect of vinorelbine on TNF $\alpha$  and IL-11 mRNA expression, and counteracted the stimulatory effect of radiation on TNF $\alpha$  mRNA expression (Figure 9).




**Figure 9.** Effects of melatonin on docetaxel-, vinorelbine-, and radiation-induced changes on the expression of antiadipogenic cytokines: (A) tumor necrosis factor  $\alpha$  (TNF $\alpha$ ), (B) interleukin 6 (IL-6), and (C) IL-11. Data are expressed as the percentage of control group (mean  $\pm$  SEM). a,  $p < 0.05$  vs. C; b,  $p < 0.05$  vs. D (1  $\mu$ M); c,  $p < 0.05$  vs. V (1  $\mu$ M); d,  $p < 0.01$  vs. R. C: control, M: melatonin, D: docetaxel, V: vinorelbine, R: radiation.

### 2.6. Effects of Melatonin on Docetaxel-, Vinorelbine-, and Radiation-Induced Changes on cyclooxygenase 1 (COX-1) and COX-2 mRNA Expression in Human Breast Preadipocytes

Since COX mRNA expression has been related with aromatase mRNA expression, we studied COX-1 and COX-2 mRNA expression in preadipocytes. Docetaxel and radiation inhibited COX-1 and COX-2 mRNA expression. Melatonin inhibited COX-1 and COX-2 mRNA expression and potentiated the inhibitory effect induced by docetaxel and radiation on COX-1 and COX-2 mRNA expression (Figure 10).





**Figure 10.** Effects of melatonin on docetaxel-, vinorelbine-, and radiation-induced changes on cyclooxygenases (COX) mRNA expression: (A) COX-1 and (B) COX-2. Data are expressed as the percentage of control group (mean  $\pm$  SEM). a,  $p < 0.001$  vs. C; b,  $p < 0.01$  vs. C; c,  $p < 0.05$  vs. D (1  $\mu$ M); d,  $p < 0.001$  vs. V (1  $\mu$ M); e,  $p < 0.05$  vs. R. C: control, M: melatonin, D: docetaxel, V: vinorelbine, R: radiation.

### 3. Discussion

In the formation of breast cancer, it is very important the interactions between different cells (adipocytes, preadipocytes, fibroblasts, and endothelial, adaptive, and innate immune system cells) within the tumor microenvironment and numerous signaling factors that contribute to stimulation or suppression of tumor growth [1,2]. The promotion of mammary tumors takes place inside a well-known desmoplastic reaction that involves the recruitment and accumulation of undifferentiated fibroblasts with a high aromatase activity and expression around malignant cells. Paracrine interactions between breast cancer cells and adjacent fibroblasts and endothelial cells are responsible for estrogen synthesis and lack of adipogenic differentiation in breast cancer tissue [15–17]. Malignant epithelial cells secrete cytokines, such as  $\text{TNF}\alpha$ , IL-6, and IL-11, which inhibit the differentiation of the fibroblasts that surround tumor cells into adipocytes and increase their aromatase activity and expression [4,18]. Thus, tumor cells are surrounded by a large number of cells able to synthesize estrogens which promote malignant cell growth. In addition, the dynamic changes that take place within tumor microenvironment sometimes enable malignant cells to develop resistance to chemotherapeutic drugs or to radiation, because they induce a sublethal exposition of tumor cells to the different treatments [19]. Melatonin, within its antitumor actions, counteracts the effects of estrogens through different actions by interacting at different levels with estrogen signaling pathways [7–9,20–22]. Within these actions, melatonin stimulates the differentiation of preadipocytes to adipocytes and decreases aromatase activity and expression in adipose fibroblasts and cancer-associated fibroblasts, by reducing the production of estrogens near tumor cells [23,24]. Therefore, in our study, we investigated the effects of chemotherapeutics (docetaxel or vinorelbine) and ionizing radiation on the differentiation of

human breast preadipocytes and its modulation by melatonin. The present study demonstrated that docetaxel, vinorelbine, and radiation have effects not only on tumor cells but also on the rest of the cells that form the tumor microenvironment. Docetaxel and vinorelbine inhibited cell proliferation and increased the triglyceride content of adipocytes, an indicator of adipogenic differentiation, both in breast preadipocytes cultures and in co-cultures of breast preadipocytes with human breast cancer cells. Since it is known that malignant cells secrete antiadipogenic cytokines that prevent the differentiation of preadipocytes to adipocytes near the tumor, being this inhibition of differentiation the main mechanism responsible for desmoplastic reaction, in some experiments, we used co-cultures of breast preadipocytes and breast cancer cells. Melatonin 1 mM potentiated this stimulatory effect on differentiation of preadipocytes induced by docetaxel and vinorelbine. Until now, there are several studies about melatonin and adipogenesis but with contradictory results. Thus, some authors [23,25,26] described a dose-dependent stimulatory action of melatonin on adipocyte differentiation in 3T3-L1 fibroblasts by upregulating C/EBP $\alpha$  and PPAR $\gamma$ . Recently, Yang et al. (2017) [27] described that melatonin promotes the differentiation of bovine intramuscular adipocytes into adipocytes by increasing C/EBP $\alpha$ , C/EBP $\beta$ , and PPAR $\gamma$  mRNA expression via MT2 melatonin receptor. However, some studies point to the fact that melatonin inhibits adipogenic differentiation through a downregulation of C/EBP $\alpha$ , C/EBP $\beta$ , and PPAR $\gamma$  [28]. Thus, the implication of melatonin in adipogenesis is not completely clear and the melatonin actions might be different depending on animal species or the melatonin doses employed. Raloxifene, a selective estrogen receptor modulator like melatonin, also stimulates adipocyte differentiation of 3T3-L1 cells [29]. The conversion of preadipocytes into mature adipocytes depends on a cascade of activation of transcription factors that modulates the expression of different proteins involved in the establishment of the mature fat cell phenotype. In this sequence of activation, two of the main regulators of terminal adipogenesis are PPAR $\gamma$  and C/EBP $\alpha$ , which induce the transcription of several adipocyte genes encoding proteins and enzymes involved in promoting and maintaining the adipocyte phenotype [29,30]. Docetaxel and vinorelbine significantly increased C/EBP $\alpha$  and PPAR $\gamma$  mRNA expression. Melatonin treatment potentiated the stimulatory effect of both chemotherapeutics on C/EBP $\alpha$  and PPAR $\gamma$  mRNA expression. The effects of melatonin on normal and cancer cells biology depend on different factors like concentration, time of exposure, or specific characteristics of cells. Previously, it has been described that melatonin exerts an inhibitory effect on human breast cancer cells proliferation only at nanomolar concentration [9,18,20]. However, high melatonin doses are required to obtain oncostatic effects in other types of normal and cancer cells, like human prostate cancer cell, neuroblastoma, human Ewing sarcoma, colon cancer cells, hepatocarcinoma cells, fibroblasts, or endothelial cells [18,23,31,32]. Melatonin crosses the blood–brain barrier because it is a highly lipid-soluble indolamine and its concentration in the cerebrospinal fluid is higher than in blood. It is known that melatonin is also 3 orders of magnitude more concentrated in neoplastic and adipose tissue of the breast [33]. These high levels of melatonin in some tissues may contribute to explaining why high concentrations of melatonin are necessary to obtain some oncostatic actions of melatonin.

On the other hand, in our study, radiation reduced both cell proliferation and intracytoplasmic triglyceride content. Melatonin 1 mM decreased cell proliferation and counteracted the effect of radiation and increased adipogenic differentiation. The inhibitory effect of radiation on adipogenic differentiation was also mediated by the regulation of C/EBP $\alpha$  and PPAR $\gamma$ . Thus, radiation decreased C/EBP $\alpha$  and PPAR $\gamma$  mRNA expression. Melatonin counteracted the inhibitory effect exerted by radiation and significantly increased C/EBP $\alpha$  and PPAR $\gamma$  mRNA expression. Our data are consistent with previous observations that demonstrated that irradiation inhibits the osteogenic and adipogenic ability of bone marrow mesenchymal stem cells [34]. Ultraviolet A also inhibits adipogenic differentiation of human adipose tissue-derived mesenchymal stem cells by reducing C/EBP $\alpha$  and PPAR $\gamma$  mRNA expression [35]. In a recent study, Shreder et al. (2018) [36] described that high X-ray doses induce a dose-dependent decrease of the proliferation and an increase in lipid accumulation in human preadipocytes. They described that the expression of markers of adipogenic differentiation (C/EBP $\alpha$ , PPAR $\gamma$ , and C/EBP $\beta$ ) is not significantly changed upon irradiation and they suggested a radiation-induced response relates

to inflammation. The stimulatory effects of melatonin on C/EBP $\alpha$  and PPAR $\gamma$  mRNA expression have already been described in 3T3-L1 fibroblasts through known melatonin receptor-mediated mechanisms [23].

Another marked undifferentiated preadipocyte phenotype is the aromatase expression [15,37]. Docetaxel and radiation decrease aromatase activity and expression and this effect was significantly potentiated by melatonin treatment. At this moment, the effects of ionizing radiation on the local estrogen biosynthesis are not well known. In the case of docetaxel, it has been described that it decreases intratumoral aromatase mRNA levels in breast tumors [38]. Our results are in agreement with those describing that melatonin decreases aromatase activity and expression in human breast cancer, glioma, and endothelial cells as well as in 3T3-L1 fibroblasts or breast cancer-associated fibroblasts [22–24,39,40]. Breast adipose fibroblasts are the major source of local estrogen biosynthesis and maintain low levels of aromatase expression via promoter I.4. However, in breast tumor fibroblasts and breast malignant epithelial cells, aromatase expression is induced via stimulation of promoters II and I.3 [3]. In our study, the inhibition of aromatase mRNA expression induced by docetaxel and vinorelbine can be explained through a downregulation of the promoter II mRNA expression. Melatonin inhibited promoter II and I.3 mRNA expression and potentiated the inhibitory effect induced by docetaxel and radiation on promoter II. It is known that melatonin downregulates aromatase mRNA expression and the gene expression of aromatase promoter II, I.3 and I.4 in human breast cancer cells and in breast adipose fibroblasts [23,24]. The increases of aromatase promoters II and I.3 in breast adipose fibroblasts are also related with the increase in cellular cAMP levels through PGE<sub>2</sub> secreted by malignant epithelial cells [41]. A relationship between aromatase and the expression of COX enzymes has been proposed, in a way that an increased COX activity elevates PGE<sub>2</sub> levels, which increase intracellular cAMP that activate promoters II and I.3 and result in an increased aromatase expression. COX-1 and COX-2 are rate-limiting enzymes that catalyze the conversion of arachidonic acid to prostaglandins. COX-1 is constitutively expressed in most cells and tissues and COX-2 is undetectable but inducible in inflammation or cancer [42–44]. High levels of PGE<sub>2</sub> have been associated with stimulation of angiogenesis and cancer development [45]. In our study, docetaxel and radiation decreased both COX-1 and COX-2 mRNA expression and melatonin inhibited the expression of both COX and potentiated the inhibitory effect of docetaxel and radiation. This inhibition of COX expression could explain the reduction of promoter II mRNA expression and the inhibition of aromatase expression exerted by docetaxel and radiation. Docetaxel also inhibits COX-2 induction in vascular smooth muscle cells [46]. However, docetaxel induces COX-2 and increases PGE<sub>2</sub> synthesis in tumor cells, which is a disadvantage in anticancer therapy with docetaxel, since this fact affects tumor development and metastasis [47]. In human breast cancer cells, one of the mechanisms through melatonin modulates aromatase enzyme is also via a downregulation of COX-1 and COX-2 mRNA expression [48]. Then, we can suggest that, in our study, the downregulation of COX mRNA expression could decrease the production of PGE<sub>2</sub> by preadipocytes and the lower levels of PGE<sub>2</sub> diminish the intracellular levels of cAMP and consequently the activation of aromatase promoter II that result in decreased aromatase expression.

In addition, as we previously described, breast cancer cells secrete antiadipogenic cytokines that inhibit the differentiation of preadipocytes to adipocytes and increase their aromatase activity and expression [3,4,49–51]. It has been described that melatonin, in co-cultures of human breast cancer cells and 3T3-L1 fibroblasts, decreases the levels of TNF $\alpha$ , IL-11, and IL-6 in the culture media and downregulates TNF $\alpha$ , IL-11, and IL-6 mRNA expression in both types of cells [52]. We found that docetaxel decreased TNF $\alpha$ , IL-11, and IL-6 expression and vinorelbine reduced TNF $\alpha$  and IL-11 expression. These results agree with previous descriptions in which docetaxel downregulated intratumoral aromatase mRNA expression through an inhibition of intratumoral TNF $\alpha$  mRNA expression in human breast cancer [39]. In addition, Tsavaris et al. (2002) [53] described a decrease in TNF $\alpha$  levels in breast cancer patients after treatment with taxanes. The reduction of TNF $\alpha$ , IL-11, and IL-6 expression induced by the chemotherapeutics may also contribute toward

explaining the stimulation of differentiation exerted by them. Melatonin increased the inhibitory effect exerted by docetaxel and vinorelbine on these antiadipogenic cytokines, which explains that melatonin potentiated the stimulatory effect exerted by docetaxel and vinorelbine on differentiation of preadipocytes. However, radiation increased TNF $\alpha$  mRNA expression which justifies why radiation inhibits adipogenic differentiation. The increase of TNF $\alpha$  expression after irradiation has been also described in human adipose during radiotherapy [54]. Melatonin counteracted this radiation-induced effect and decreased TNF $\alpha$  mRNA expression stimulating adipogenic differentiation.

In summary, the results of our study indicated that chemotherapeutics, like docetaxel or vinorelbine, may play a role in the desmoplastic reaction in breast cancer. They inhibited proliferation and stimulated the differentiation of human breast preadipocytes, by increasing the expression of the two main regulators of terminal adipogenesis, C/EBP $\alpha$  and PPAR $\gamma$ , and by downregulating antiadipogenic cytokines, like TNF $\alpha$ , IL-6, or IL-11. Radiation inhibited both proliferation and differentiation of preadipocytes to adipocytes through the downregulation of C/EBP $\alpha$  and PPAR $\gamma$  and by stimulating TNF $\alpha$ . In addition, docetaxel and radiation decreased aromatase activity and expression by decreasing aromatase promoter II mRNA expression and COX-1 and COX-2 expression. Melatonin potentiated the stimulatory effect of docetaxel and vinorelbine on differentiation and its inhibitory effect on aromatase activity and expression, by increasing the stimulatory effect on C/EBP $\alpha$  and PPAR $\gamma$  and by increasing the downregulation of antiadipogenic cytokines and COX expression. In combination with radiation, melatonin counteracted the inhibitory effect of radiation on differentiation of preadipocytes, by increasing C/EBP $\alpha$  and PPAR $\gamma$  expression and by decreasing the TNF $\alpha$  expression induced by radiation. Melatonin also potentiated the inhibitory effect exerted by radiation on aromatase activity and expression by increasing the downregulation of promoter II, and COX-1 and COX-2 expression. Within tumor microenvironment, melatonin modulates the response of preadipocytes (differentiation, aromatase activity, and expression) to chemotherapeutic drugs or to radiation. Recently, some studies [2,55,56] suggest melatonin as an adjuvant for chemotherapy and radiotherapy sensitization showing synergistic antitumoral effects.

## 4. Materials and Methods

### 4.1. Cells and Culture Conditions

Human breast preadipocytes were purchased from ZenBio, Inc (Research Triangle Park, NC, USA). They were maintained as monolayer cultures in 58,2 cm<sup>2</sup> plastic culture plates in Preadipocyte Medium (PM-1) (ZenBio, Inc, Research Triangle Park NC, USA) supplemented with penicillin (20 units/mL) and streptomycin (20  $\mu$ g/mL) (Sigma-Aldrich, Madrid, Spain) at 37 °C in a humid atmosphere containing 5% CO<sub>2</sub>. Cells were cultured until reaching confluence and then they were differentiated into the adipocyte phenotype with Adipocyte Differentiation Medium (DM-2) (ZenBio, Inc, Research Triangle Park NC, USA) for 14 days. Medium change was realized every 2 days. To determine the effects during the course of adipocyte differentiation, docetaxel (1  $\mu$ M), vinorelbine (1  $\mu$ M), and/or melatonin (1 mM or 1 nM), or vehicle were maintained in the cultures during the fourteen-day period. To study the effects on differentiation of human breast preadipocyte cells, docetaxel 1  $\mu$ M, vinorelbine 1  $\mu$ M, and/or melatonin 1 mM or 1 nM) or vehicle were added to the cultures at day 14 of the differentiation period and maintained for 72 h. In the other experiments, cells were cultured for 24 h in Preadipocyte Medium (PM-1), irradiated at 8 Gy and differentiated into the adipocyte phenotype with Adipocyte Differentiation Medium (DM-2) in the presence or not of melatonin (1 mM or 1 nM) for 14 days. To study the effects on differentiation of human breast preadipocyte cells, they were irradiated at day 14 of the differentiation period at 8 Gy and incubated in the presence or not of melatonin (1 mM or 1 nM) for 72 h.

#### 4.2. Co-culture of Human Breast Preadipocytes and MCF-7 Cells

In some experiments, we employed co-cultures of human breast preadipocytes and human breast cancer cells (MCF-7). Based on previous works [52], cells were co-cultured using Falcon 24-multiwell plates and Falcon cell culture inserts. Human breast preadipocytes were plated ( $90 \times 10^3$  cells/well) on the bottom wells in Preadipocyte Medium (PM-1) and incubated overnight. At the same time, MCF-7 cells ( $5 \times 10^3$  cells) were seeded on the permeable membrane ( $0.45 \mu\text{m}$ ) of the tissue-culture inserts in DMEM supplemented with 10% FBS also for 24 h. Human breast preadipocytes and MCF-7 cells were cultured separately for 24 h to establish attachment. After 24 h, MCF-7-seeded inserts were moved over human breast preadipocytes cultures in the 6-well plates to create the hanging co-culture setup and the medium was changed to the Adipocyte Differentiation Medium (DM-2) with docetaxel ( $1 \mu\text{M}$ ), vinorelbine ( $1 \mu\text{M}$ ), and/or melatonin ( $1 \text{mM}$  or  $1 \text{nM}$ ), or vehicle. In some experiments, cells were irradiated at 8 Gy and cultured in the presence or not of melatonin ( $1 \text{mM}$  or  $1 \text{nM}$ ) or vehicle. Due to the membrane pore size and diffusional distance between cells within this setup, cell-to-cell contact was prevented but paracrine signalling could occur between endothelial cells in the 24-well plate and epithelial cells on the insert. After 14 days, human breast preadipocyte differentiated in the bottom plate were evaluated for differentiation to mature adipocytes (quantification of triglycerides by Oil Red O staining method), for proliferative indices (MTT method) or for aromatase activity.

#### 4.3. Ionizing Radiation Treatment

Human breast preadipocytes and MCF-7 cells were exposed to X irradiation using a model YXLON SMART 200 tube (Yxlon International, Hamburg, Germany) at room temperature. We used 8 Gy radiation as the optimal radiation dose, as previously described [11].

#### 4.4. Measurement of Cellular Proliferation

Cell proliferation was measured by the MTT [3(4,5dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide] method, since the reduction of tetrazolium salts is broadly accepted as an accurate way to study cell proliferation [57]. At the end of the experiments, cell proliferation was measured reading the absorbance at 570 nm in a microplate reader (Labsystems Multiskan RC 351, Vienna, VA, USA). MTT was obtained from Molecular Probes Inc. (Eugene, OR, USA).

#### 4.5. Quantitation of Triglycerides by Oil Red O Staining

We used the Oil Red O staining method to quantify the accumulation of intracytoplasmic triglyceride [15]. As previously described [52], cells were fixed in 10% *p*-formaldehyde, washed, and stained with oil red before photographing ( $20\times$ ). To determine the content of lipids, a colorimetric method was used.

#### 4.6. Measurement of Cellular Aromatase Activity

Aromatase activity in human breast preadipocytes cells was measured by the tritiated water release assay, based on the formation of tritiated water during aromatization of a labeled androgenic substrate [ $1\beta\text{-}^3\text{H(N)}$ ]-androst-4-ene-3,17-dione [58]. At the end of the experiments, human breast preadipocytes differentiated into mature adipocytes in the presence of docetaxel ( $1 \mu\text{M}$ ), vinorelbine ( $1 \mu\text{M}$ ), and/or melatonin ( $1 \text{mM}$  or  $1 \text{nM}$ ), or vehicle during the course of adipocyte differentiation or these human breast preadipocytes completely differentiated into adipocytes and exposed for 72 h to docetaxel ( $1 \mu\text{M}$ ), vinorelbine ( $1 \mu\text{M}$ ), and/or melatonin ( $1\text{mM}$  or  $1 \text{nM}$ ), or vehicle (ethanol at a final concentration lower than 0.0001%) were cultured with serum-free media containing 100 nM [ $1\beta\text{-}^3\text{H(N)}$ ]-androst-4-ene-3,17-dione] (NEN Life Science Products, Boston, MA, USA) ( $25\text{--}30 \text{Ci/mM}$ ) in the presence of chemotherapeutics and/or melatonin or irradiated. As previously described [10], successive extractions with organic solvents were performed to separate the steroids from the aqueous phase.



#### 4.7. Measurement of Specific mRNA Gene Expression

At the end of the experiments, analyses of different genes mRNA expression in human breast preadipocytes were realized by real-time RT-PCR. The total cellular RNA was purified with the Nucleospin RNA II Kit (Macherey-Nagel, Düren, Germany) following the manufacturer's instructions. Integrity of RNA was assessed by electrophoresis in ethidium bromide-stained 1% agarose-Tris-borate EDTA gels. The absorbance ratio of  $A_{260\text{nm}}/A_{280\text{nm}}$  was greater than 1.8. For cDNA synthesis, 0.5  $\mu\text{g}$  of total RNA was denatured at 65 °C for 10 min and reverse transcribed for 50 min at 45 °C with cDNA Synthesis kit (Bioline, London, UK) in a final volume of 20  $\mu\text{L}$  in the presence of 500 ng of oligo (dT) 12–18 primer. The primers used for amplification (Sigma Genosys Ltd., Cambridge, UK), using the housekeeping gene *S14* as a control quantification, are listed in Table 1. RT-PCRs were performed in a MX3005P system (Stratagene, La Jolla, CA, USA) using Brilliant  $\text{®SYBR } \text{®Green}$  PCR Master Mix (Applied Biosystems, Madrid, Spain) following the manufacturer's instructions. Amplifications were performed for 40 cycles using the following temperature profile: 60 °C, 45 s (annealing); 72 °C, 30 s (extension); and 95 °C, 30 s (denaturation). Each reaction was run ninefold by quadruplicate. Melting curves were performed to verify that only a single product with no primer-dimers was amplified. For the primers used, there were no differences between transcription efficiencies, and the fold-change in each sample was calculated by the  $2^{-\Delta\Delta\text{Ct}}$  method [59]. The fractional cycle at which the amount of amplified targets became significant (Ct) was automatically calculated by the PCR program.

**Table 1.** Primers used for amplification of mRNA transcripts.

mRNA	Sequence	Concentration (nM)
hARO fw	5'- GTCGTGGACTTGGTCATGC -3'	100
hARO rv	5'- CGAGTCTGTGCATCCTTCC -3'	100
hC/EBP $\alpha$ fw	5'- AGGTGCTGGAGCTGACCAGT -3'	200
hC/EBP $\alpha$ rv	5'- AAGCCTCGAGATCCGGCGAC -3'	200
COX-1 fw	5'- ACCCGCACGGGCTATTCCGGC -3'	200
COX-1 rv	5'- AGGCGCATGAGCATCTCTCGG -3'	200
COX-2 fw	5'- ATGTATGAGTGTGGGATTTGA -3'	200
COX-2 rv	5'- TCCAAAATCCCTTGAAGTGGG -3'	200
hIL-6 fw	5'- AGGAGACTTGCCTGGTGAAA -3'	200
hIL-6 rv	5'- CAGGGGTGGTTATTGCATCT -3'	200
hIL-11 fw	5'- GCTGGTTTCGAACTCCTGAC -3'	200
hIL-11 rv	5'- CAGGGTGACTTGTGGAACCT -3'	200
hpII fw	5'- CTCTGAAGCAACAGGAGCTATAGA -3'	100
hpII rv	5'- CAGGCACGATGCTGGTGATG -3'	100
hpl.3 fw	5'- GGGCTTCCTTGTTTTGACTGTAA -3'	200
hpl.3 rv	5'- AGAGGGGGCAATTTAGAGTCTGTT -3'	200
hPPAR $\gamma$ fw	5'- GATGCACTGCCTATGACACTT -3'	400
hPPAR $\gamma$ rv	5'- AGAGGTCCACAGAGCTGATTCC -3'	400
hS14 fw	5'- TCCTGCGAGTGCTGTCAGAG -3'	100
hS14 rv	5'- TCACCGCCTACACATCAAAC -3'	100
hTNF $\alpha$ fw	5'- TGGGGTTTGTGAAACTGTGA -3'	50
hTNF $\alpha$ rv	5'- GTTCCTGCACATTCCCTCTC -3'	50

#### 4.8. Statistical Analysis

Statistical analyses were realized using GraphPad Prism software. The data are expressed as the mean  $\pm$  the standard error of the mean (SEM). Differences between groups were analyzed by using one way analysis of variance (ANOVA), followed by the Student–Newman–Keuls test. Results were considered as statistically significant at  $p < 0.05$ .

**Author Contributions:** A.G.-G., E.G.N., and C.S.-F. carried out culture experiments, measurement of cellular proliferation, enzymatic activities, and RT-PCR; C.M.-C., C.A.-G., and A.G. were involved in the conception and design of the study, data analysis, and interpretation; J.M.-M. was involved in the co-culture experiments; J.G.-A. was involved in cell irradiation; S.C. conceived experiments and was involved in the study design, data analysis, and manuscript writing. All authors reviewed the manuscript and gave final approval to the submitted version.

**Funding:** This work was supported by a grant from the Spanish Economy and Competitiveness Ministry (SAF2016-77103-P) and from Instituto de Investigación Sanitaria Valdecilla (IDIVAL) (APG/12).

**Conflicts of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

## References

1. Wang, Y.Y.; Lehuédé, C.; Laurent, V.; Dirat, B.; Dauvillier, S.; Bochet, L.; Le Gonidec, S.; Escourrou, G.; Valet, P.; Muller, C. Adipose tissue and breast epithelial cells: A dangerous dynamic duo in breast cancer. *Cancer Lett.* **2012**, *324*, 142–151. [[CrossRef](#)] [[PubMed](#)]
2. Najafi, M.; Goradel, N.H.; Farhood, B.; Salehi, E.; Solhjoo, S.; Toolee, H.; Kharazinejad, E.; Mortezaee, K. Tumor microenvironment: Interactions and therapy. *J. Cell Physiol.* **2019**, *234*, 5700–5721. [[CrossRef](#)] [[PubMed](#)]
3. Bulun, S.E.; Lin, Z.; Imir, G.; Amin, S.; Demura, M.; Yilmaz, B.; Martin, R.; Utsunomiya, H.; Thung, S.; Gurates, B.; et al. Regulation of aromatase expression in estrogen-responsive breast and uterine disease: From bench to treatment. *Pharm. Rev.* **2005**, *57*, 359–383. [[CrossRef](#)] [[PubMed](#)]
4. Meng, L.I.; Zhou, J.; Sasano, H.; Suzuki, T.; Zeitoun, K.M.; Bulun, S.E. Tumor necrosis factor  $\alpha$  and interleukin 11 secreted by malignant breast epithelial cells inhibit adipocyte differentiation by selectively down-regulating CCAAT/enhancer binding protein  $\alpha$  and peroxisome proliferator-activated receptor  $\gamma$ : Mechanism of desmoplastic reaction. *Cancer Res.* **2001**, *61*, 2250–2255. [[PubMed](#)]
5. Chen, D.; Reierstad, S.; Lu, M.; Lin, Z.; Ishikawa, H.; Bulun, S.E. Regulation of breast cancer-associated aromatase promoters. *Cancer Lett.* **2009**, *273*, 15–27. [[CrossRef](#)] [[PubMed](#)]
6. Poglio, S.; Galvani, S.; Bour, S.; André, M.; Prunet-Marcassus, B.; Pénicaud, L.; Casteilla, L.; Cousin, B. Adipose tissue sensitivity to radiation exposure. *Am. J. Pathol.* **2009**, *174*, 44–53. [[CrossRef](#)] [[PubMed](#)]
7. Sánchez-Barceló, E.J.; Cos, S.; Mediavilla, D.; Martínez-Campa, C.; González, A.; Alonso-González, C. Melatonin-estrogen interactions in breast cancer. *J. Pineal Res.* **2005**, *38*, 217–222. [[CrossRef](#)]
8. Cos, S.; González, A.; Martínez-Campa, C.; Mediavilla, M.D.; Alonso-González, C.; Sánchez-Barceló, E.J. Estrogen-signaling pathway: A link between breast cancer and melatonin oncostatic actions. *Cancer Detect. Prev.* **2006**, *30*, 118–128. [[CrossRef](#)]
9. Hill, S.M.; Belancio, V.P.; Dauchy, R.T.; Xiang, S.; Brimer, S.; Mao, L.; Hauch, A.; Lundberg, P.W.; Summers, W.; Yuan, L.; et al. Melatonin: An inhibitor of breast cancer. *Endocr. Relat. Cancer* **2015**, *22*, R183–R204. [[CrossRef](#)]
10. Martínez-Campa, C.; González, A.; Mediavilla, M.D.; Alonso-González, C.; Sánchez-Barceló, E.J.; Cos, S. Melatonin enhances the inhibitory effect of aminoglutethimide on aromatase activity in MCF-7 human breast cancer cells. *Breast Cancer Res. Treat.* **2005**, *94*, 249–254. [[CrossRef](#)]
11. Alonso-González, C.; González, A.; Martínez-Campa, C.; Gómez-Arozamena, J.; Cos, S. Melatonin sensitizes human breast cancer cells to ionizing radiation by downregulating proteins involved in double-strand DNA break repair. *J. Pineal Res.* **2015**, *58*, 189–197. [[CrossRef](#)]
12. Alonso-González, C.; González, A.; Martínez-Campa, C.; Menéndez-Menéndez, J.; Gómez-Arozamena, J.; García-Vidal, A.; Cos, S. Melatonin enhancement of the radiosensitivity of human breast cancer cells is associated with the modulation of proteins involved in estrogen biosynthesis. *Cancer Lett.* **2016**, *370*, 145–152. [[CrossRef](#)]
13. Alonso-González, C.; Menéndez-Menéndez, J.; González-González, A.; González, A.; Cos, S.; Martínez-Campa, C. Melatonin enhances the apoptotic effects and modulates the changes in gene expression induced by docetaxel in MCF-7 human breast cancer cells. *Int. J. Oncol.* **2018**, *52*, 560–570.
14. Najafi, M.; Salehi, E.; Farhood, B.; Nashtaei, M.S.; Goradel, N.H.; Khanlarkhani, N.; Namjoo, Z. Adjuvant chemotherapy with melatonin for targeting human cancers: A review. *J. Cell Physiol.* **2019**, *234*, 2356–2372. [[CrossRef](#)]



15. Ramírez-Zacarias, J.L.; Castro-Muñozledo, F.; Kuri-Harcuch, W. Quantitation of adipose conversion and triglycerides by staining intracytoplasmic lipids with Oil red O. *Histochemistry* **1992**, *97*, 493–497. [[CrossRef](#)]
16. Bulun, S.E.; Chen, D.; Lu, M.; Zhao, H.; Cheng, Y.; Demura, M.; Yilmaz, B.; Martin, R.; Utsunomiya, H.; Thung, S.; et al. Aromatase excess in cancers of breast, endometrium and ovary. *J. Steroid Biochem. Mol. Biol.* **2007**, *106*, 81–96. [[CrossRef](#)]
17. Guerrero, J.; Tobar, N.; Cáceres, M.; Espinoza, L.; Escobar, P.; Dotor, J.; Smith, P.C.; Martínez, J. Soluble factors derived from tumor mammary cell lines induce a stromal mammary adipose reversion in human and mice adipose cells. Possible role of TGF- $\beta$ 1 and TNF- $\alpha$ . *Breast Cancer Res. Treat.* **2010**, *119*, 497–508. [[CrossRef](#)]
18. Cos, S.; Alvarez-García, V.; González, A.; Alonso-González, C.; Martínez-Campa, C. Melatonin modulation of crosstalk among malignant epithelial, endothelial and adipose cells in breast cancer. *Oncol. Lett.* **2014**, *8*, 487–492. [[CrossRef](#)]
19. He, J.; Chen, Q.; Gu, H.; Chen, J.; Zhang, E.; Guo, X.; Huang, X.; Yan, H.; He, D.; Yang, Y.; et al. Therapeutic effects of the novel subtype-selective histone deacetylase (HDAC) inhibitor chidamide on myeloma-associated bone disease. *Haematologica* **2018**, *103*, 1369–1379. [[CrossRef](#)]
20. Cos, S.; González, A.; Martínez-Campa, C.; Mediavilla, M.D.; Alonso-González, C.; Sánchez-Barceló, E.J. Melatonin as a selective estrogen enzyme modulator. *Curr. Cancer Drug Tar.* **2008**, *8*, 691–702. [[CrossRef](#)]
21. Gonzalez, A.; Cos, S.; Martinez-Campa, C.; Alonso-Gonzalez, C.; Sanchez-Mateos, S.; Mediavilla, M.D.; Sanchez-Barcelo, E.J. Selective estrogen enzyme modulator (SEEM) actions of melatonin in human breast cancer cells. *J. Pineal Res.* **2008**, *45*, 86–92. [[CrossRef](#)]
22. González, A.; Martínez-Campa, C.; Mediavilla, M.D.; Alonso-González, C.; Sánchez-Barceló, E.J.; Cos, S. Inhibitory effects of pharmacological doses of melatonin on aromatase activity and expression in rat glioma cells. *Br. J. Cancer* **2017**, *97*, 755–760. [[CrossRef](#)]
23. González, A.; Alvarez-García, V.; Martínez-Campa, C.; Alonso-González, C.; Cos, S. Melatonin promotes differentiation of 3T3-L1 fibroblasts. *J. Pineal Res.* **2012**, *52*, 12–20. [[CrossRef](#)]
24. Knowler, K.C.; To, S.Q.; Takagi, K.; Miki, Y.; Sasano, H.; Simpson, E.R.; Clyne, C.D. Melatonin suppresses aromatase expression and activity in breast cancer associated fibroblasts. *Breast Cancer Res. Treat.* **2012**, *132*, 765–771. [[CrossRef](#)]
25. Maldonado, M.D.; Siu, A.W.; Sánchez-Hidalgo, M.; Acuña-Castroviejo, D.; Escames, G. Melatonin and lipid uptake by murine fibroblasts: Clinical implications. *Neuro Endocrinol. Lett.* **2006**, *27*, 601–608.
26. Kato, H.; Tanaka, G.; Masuda, S.; Ogasawara, J.; Sakurai, T.; Kizaki, T.; Ohno, H.; Izawa, T. Melatonin promotes adipogenesis and mitochondrial biogenesis in 3T3-L1 preadipocytes. *J. Pineal Res.* **2015**, *59*, 267–275. [[CrossRef](#)]
27. Yang, W.; Tang, K.; Wang, Y.; Zhang, Y.; Zan, L. Melatonin promotes triacylglycerol accumulation via MT2 receptor during differentiation in bovine intramuscular preadipocytes. *Sci. Rep.* **2017**, *7*, 15080. [[CrossRef](#)]
28. Alonso-Vale, M.I.; Peres, S.B.; Vernochet, C.; Farmer, S.R.; Lima, F.B. Adipocyte differentiation is inhibited by melatonin through the regulation of c/EBP $\beta$  transcriptional activity. *J. Pineal Res.* **2009**, *47*, 221–227. [[CrossRef](#)]
29. Ntambi, J.M.; Kim, Y.C. Adipocyte differentiation and gene expression. *J. Nutr.* **2000**, *130*, 3122S–3126S. [[CrossRef](#)]
30. Lane, M.D.; Tang, Q.Q. From multipotent stem cell to adipocyte. *Birth Defects Res. A* **2005**, *73*, 476–477. [[CrossRef](#)]
31. Mediavilla, M.D.; Sanchez-Barceló, E.J.; Tan, D.X.; Manchester, L.; Reiter, R.J. Basic mechanisms involved in the anti-cancer effects of melatonin. *Curr. Med. Chem.* **2010**, *17*, 4462–4481. [[CrossRef](#)]
32. Alvarez-García, V.; González, A.; Alonso-González, C.; Martínez-Campa, C.; Cos, S. Antiangiogenic effects of melatonin in endothelial cell cultures. *Microvascular Res.* **2013**, *87*, 25–33. [[CrossRef](#)]
33. Maestroni, G.J.; Conti, A. Melatonin in human Breast cancer tissue: Association with nuclear grade and estrogen receptor status. *Lab. Invest.* **1996**, *75*, 557–561.
34. Wang, Y.; Zhu, G.; Wang, J.; Chen, J. Irradiation alters the differentiation potential of bone marrow mesenchymal stem cells. *Mol. Med. Rep.* **2016**, *13*, 213–223. [[CrossRef](#)]
35. Lee, J.; Lee, J.; Jung, E.; Kim, Y.S.; Roh, K.; Jung, K.H.; Park, D. Ultraviolet A regulates adipogenic differentiation of human adipose tissue-derived mesenchymal stem cells via up-regulation of kruppel-like factor 2. *J. Biol. Chem.* **2010**, *285*, 32647–32656. [[CrossRef](#)]

36. Schreder, K.; Rapp, F.; Tsoukala, I.; Rzeznik, V.; Wabitsch, M.; Fischer-Posovszky, P.; Fournier, C. Impact of X-ray exposure on the proliferation and differentiation of human pre-adipocytes. *Int. J. Mol. Sci.* **2018**, *19*, 2717. [[CrossRef](#)]
37. Russo, J.; Russo, I.H. The role of estrogen in the initiation of breast cancer. *J. Steroid Biochem. Mol. Biol.* **2006**, *102*, 89–96. [[CrossRef](#)]
38. Miyoshi, Y.; Kim, S.J.; Akazawa, K.; Kamigaki, S.; Ueda, S.; Yanagisawa, T.; Inoue, T.; Taguchi, T.; Tamaki, Y.; Noguchi, S. Down-regulation of intratumoral aromatase messenger RNA levels by docetaxel in human breast cancers. *Clin. Cancer Res.* **2004**, *10*, 8163–8169. [[CrossRef](#)]
39. Cos, S.; Martínez-Campa, C.; Mediavilla, M.D.; Sánchez-Barceló, E.J. Melatonin modulates aromatase activity in MCF-7 human breast cancer cells. *J. Pineal Res.* **2005**, *38*, 136–142. [[CrossRef](#)]
40. Alvarez-García, V.; González, A.; Martínez-Campa, C.; Alonso-González, C.; Cos, S. Melatonin modulates aromatase activity and expression in endothelial cells. *Oncol. Rep.* **2013**, *29*, 2058–2064. [[CrossRef](#)]
41. Brueggemeier, R.W.; Richards, J.A.; Petrel, T.A. Aromatase and cyclooxygenases: Enzymes in breast cancer. *J. Steroid Biochem. Mol. Biol.* **2003**, *86*, 501–507. [[CrossRef](#)]
42. Liu, X.-H.; Rose, D.P. Differential expression and regulation of cyclooxygenase-1 and -2 in two human breast cancer cell lines. *Cancer Res.* **1996**, *56*, 5125–5127.
43. Erovic, B.M.; Woegerbauer, M.; Pammer, J.; Selzer, E.; Grasl, M.C.; Thurnher, D. Strong evidence for up-regulation of cyclooxygenase-1 in head and neck cancer. *Eur. J. Clin. Invest.* **2008**, *38*, 61–66. [[CrossRef](#)]
44. Díaz-Cruz, E.S.; Shapiro, C.L.; Brueggemeier, R.W. Cyclooxygenase inhibitors suppress aromatase expression and activity in breast cancer cells. *J. Clin. Endocrinol. Metab.* **2005**, *90*, 2563–2570. [[CrossRef](#)]
45. Howe, L.R. Inflammation and breast cancer. Cyclooxygenase/prostaglandin signaling and breast cancer. *Breast Cancer Res.* **2007**, *9*, 210. [[CrossRef](#)]
46. Nakano, T.; Goto, K.; Wakabayashi, I. Docetaxel inhibits cyclooxygenase-2 induction in vascular smooth muscle cells. *Eur. J. Pharmacol.* **2011**, *654*, 150–154. [[CrossRef](#)]
47. Subbaramaiah, K.; Marmo, T.P.; Dixon, D.A.; Dannenberg, A.J. Regulation of cyclooxygenase-2 mRNA stability by taxanes: Evidence for involvement of p38, MAPKAPK-2 and HuR. *J. Biol. Chem.* **2003**, *278*, 37637–37647. [[CrossRef](#)]
48. Martínez Campa, C.; González, A.; Mediavilla, M.D.; Alonso-González, C.; Alvarez-García, V.; Sánchez-Barceló, E.J.; Cos, S. Melatonin inhibits aromatase promoter expression by regulating cyclooxygenases expression and activity in breast cancer cells. *Br. J. Cancer* **2009**, *101*, 1613–1619. [[CrossRef](#)]
49. Torti, F.M.; Torti, S.V.; Larrick, J.W.; Ringold, G.M. Modulation of adipocyte differentiation by tumor necrosis factor and transforming growth factor  $\beta$ . *J. Cell Biol.* **1989**, *108*, 1105–1113. [[CrossRef](#)]
50. Keller, D.C.; Du, X.X.; Srour, E.F.; Hoffman, R.; Williams, D.A. Interleukin-11 inhibits adipogenesis and stimulates myelopoiesis in human long-term marrow cultures. *Blood* **1993**, *82*, 1428–1435.
51. Rubin, G.L.; Zhao, Y.; Kalus, A.M.; Simpson, E.R. Peroxisome proliferator-activated receptor  $\gamma$  ligands inhibit estrogen biosynthesis in human breast adipose tissue: Possible implications for breast cancer therapy. *Cancer Res.* **2000**, *60*, 1604–1608.
52. Alvarez-García, V.; González, A.; Alonso-González, C.; Martínez-Campa, C.; Cos, S. Melatonin interferes in the desmoplastic reaction in breast cancer by regulating cytokine production. *J. Pineal Res.* **2012**, *52*, 282–290. [[CrossRef](#)]
53. Tsavaris, N.; Kosmas, C.; Vadiaka, M.; Kanelopoulos, P.; Boulamatsis, D. Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes. *Br. J. Cancer* **2002**, *87*, 21–27. [[CrossRef](#)]
54. Meng, G.; Tang, X.; Yang, Z.; Benesch, M.G.K.; Marshall, A.; Murray, D.; Hemmings, D.G.; Wuest, F.; McMullen, T.P.W.; Brindley, D.N. Implications for breast cancer treatment from increased autotaxin production in adipose tissue after radiotherapy. *FASEB J.* **2017**, *31*, 4064–4077. [[CrossRef](#)]
55. Farhood, B.; Goradel, N.H.; Mortezaee, K.; Khanlarkhani, N.; Salehi, E.; Nashtaei, M.S.; Mirtavoos-Mahyari, H.; Motevaseli, E.; Shabeeb, D.; Musa, A.E.; et al. Melatonin as an adjuvant in radiotherapy for radioprotection and radiosensitization. *Clin. Transl. Oncol.* **2019**, *21*, 268–279. [[CrossRef](#)]
56. Martínez-Campa, C.; Menéndez-Menéndez, J.; Alonso-González, C.; González, A.; Álvarez-García, V.; Cos, S. What is known about melatonin, chemotherapy and altered gene expression in breast cancer. *Oncol. Lett.* **2017**, *13*, 2003–2014. [[CrossRef](#)]

57. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. *J. Immunol. Methods* **1983**, *65*, 55–63. [[CrossRef](#)]
58. Ackerman, G.E.; Smith, M.E.; Mendelson, C.R.; MacDonald, P.C.; Simpson, E.R. Aromatization of androstenedione by human adipose tissue stromal cells in monolayer culture. *J. Clin. Endocrinol. Metab.* **1981**, *53*, 412–417. [[CrossRef](#)]
59. Livak, K.J.; Schmittgen, T.D. Analysis of relative gene expression data using real-time quantitative PCR and the  $2^{-\Delta\Delta C(T)}$  method. *Methods* **2001**, *25*, 402–408. [[CrossRef](#)]



© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).